P P Tak Selected Research

Rheumatoid Arthritis

08/2008	The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.
08/2008	Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study.
06/2008	Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.
01/2008	Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
08/2007	Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.
06/2007	Rheumatoid arthritis in Dubai--delayed diagnosis and low usage of disease modifying antirheumatic drugs.
11/2006	Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis.
10/2006	CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells.
12/2005	Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis.
11/2005	The role of chemokines in rheumatoid arthritis and osteoarthritis.
05/2005	Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
05/2005	Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis.
01/2005	A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
09/2004	Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
05/2004	T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.
07/2003	Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
01/2003	Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls.
12/2002	Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.
10/2002	Is expression of intracellular citrullinated proteins in synovial tissue specific for rheumatoid arthritis? Comment on the article by Baeten et al.
09/2001	Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis.
01/2001	Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis.
10/2000	Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines.
08/2000	Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.
07/2000	Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.
03/2000	Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides.
02/2000	The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.

Articles by Research Topic

Disease

26	Rheumatoid Arthritis 08/2008 - 02/2000
5	Inflammation 10/2004 - 02/2000
4	Osteoarthritis 12/2005 - 12/2002
3	Arthritis (Polyarthritis) 09/2008 - 03/2000
3	Experimental Arthritis 06/2007 - 08/2000
1	Arthralgia (Joint Pain) 09/2008
1	Necrosis 08/2008
1	Sjogren's Syndrome (Sjogren Syndrome) 02/2006
1	Reactive Arthritis (Reiter Disease) 12/2005
1	Joint Diseases (Joint Disease) 10/2004

Drug/Important Bio-Agent (IBA)

4	Methotrexate (Mexate)FDA LinkGeneric 08/2008 - 07/2000
4	Interferon-betaIBA 06/2007 - 02/2000
3	ChemokinesIBA 11/2005 - 09/2001
3	Granzymes (Granzyme)IBA 05/2005 - 01/2001
3	leflunomide (Arava)FDA LinkGeneric 09/2004 - 07/2000
2	infliximab (Remicade)FDA Link 08/2008 - 05/2005
2	CytokinesIBA 07/2003 - 10/2000
2	Matrix MetalloproteinasesIBA 07/2003 - 09/2001
1	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2008
1	cyclic citrullinated peptideIBA 09/2008
1	Anti-Idiotypic AntibodiesIBA 09/2008
1	everolimusIBA 08/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2008
1	rituximab (Mabthera)FDA Link 06/2008
1	TACI receptor-IgG Fc fragment fusion proteinIBA 01/2008
1	Interferon Type IIBA 08/2007
1	Antirheumatic Agents (DMARD)IBA 06/2007
1	Transcription Factors (Transcription Factor)IBA 11/2006
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2006
1	GTP Phosphohydrolases (GTPases)IBA 10/2006
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 02/2006
1	Rheumatoid FactorIBA 05/2005
1	C-Reactive ProteinIBA 05/2005
1	interferon beta 1a FDA LinkGeneric 01/2005
1	OsteoprotegerinIBA 01/2003
1	Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)IBA 12/2002
1	Proteins (Proteins, Gene)IBA 10/2002
1	Phosphotransferases (Kinase)IBA 08/2001
1	Interleukin-8 (Interleukin 8)IBA 01/2001
1	Proteoglycans (Proteoglycan)IBA 01/2001
1	Peptidoglycan (Murein)IBA 10/2000
1	NF-kappa B (NF-kB)IBA 08/2000
1	Viral DNAIBA 05/2000
1	Bacterial DNAIBA 03/2000
1	Metalloproteases (Metalloproteinases)IBA 02/2000